Roger Bosse (PerkinElmer)

article

Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments

6 September 2018 | By Roger Bosse (PerkinElmer)

Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.

whitepaper

Application note: High throughput quantitation of cytokine biomarkers using LANCE Ultra TR-FRET assays

4 January 2018 | By Jen Carlstrom (PerkinElmer), Roger Bosse (PerkinElmer), Stephen Hurt (PerkinElmer)

In this application note, PerkinElmer demonstrates the sensitivity, robust performance, and HTS suitability of the LANCE Ultra cytokine biomarker kits.